W. Shimp

发表

The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?

D. Cohn, W. Shimp, 2015, Gynecologic oncology reports.

Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences.

W. Hrushesky, Akhil Kumar, S. Davis, 2012, The American journal of managed care.

Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.

W. Hrushesky, Akhil Kumar, S. Davis, 2012, Journal of oncology practice.

Overuse and Misuse of Adjuvant Chemotherapy for Stages I and II Non-Small Cell Lung Cancer Chemotherapy: Empirical Findings from a Privately Insured Population

K. Knopf, C. Bennett, W. Shimp, 2015 .

Lack of age-dependent cisplatin nephrotoxicity.

B. Kennedy, W. Hrushesky, W. Shimp, 1984, The American journal of medicine.

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature.

P. Argenta, R. Kothari, J. Carter, 2010, Archive of oncology.

Interpretation of surrogate endpoints in the era of the 21st Century Cures Act

K. Knopf, C. Bennett, W. Hrushesky, 2016, British Medical Journal.

Use, misuse, and overuse of white cell growth factors (GF) in community oncology practices in southeastern United States.

C. Bennett, W. Hrushesky, A. Schorer, 2014 .

How Long Is This Going to Take?

W. Shimp, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.